IL305665A - Bifunctional degraders of galactose-deficient immunoglobulins - Google Patents

Bifunctional degraders of galactose-deficient immunoglobulins

Info

Publication number
IL305665A
IL305665A IL305665A IL30566523A IL305665A IL 305665 A IL305665 A IL 305665A IL 305665 A IL305665 A IL 305665A IL 30566523 A IL30566523 A IL 30566523A IL 305665 A IL305665 A IL 305665A
Authority
IL
Israel
Prior art keywords
optionally substituted
group
groups
moiety
independently
Prior art date
Application number
IL305665A
Other languages
English (en)
Hebrew (he)
Inventor
Gene M Dubowchik
David Spiegel
Reese M Caldwell
Original Assignee
Biohaven Therapeutics Ltd
Gene M Dubowchik
David Spiegel
Reese M Caldwell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd, Gene M Dubowchik, David Spiegel, Reese M Caldwell filed Critical Biohaven Therapeutics Ltd
Publication of IL305665A publication Critical patent/IL305665A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL305665A 2021-03-10 2022-03-10 Bifunctional degraders of galactose-deficient immunoglobulins IL305665A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163159383P 2021-03-10 2021-03-10
PCT/US2022/019658 WO2022192478A1 (en) 2021-03-10 2022-03-10 Bifunctional degraders of galactose-deficient immunoglobulins

Publications (1)

Publication Number Publication Date
IL305665A true IL305665A (en) 2023-11-01

Family

ID=83227063

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305665A IL305665A (en) 2021-03-10 2022-03-10 Bifunctional degraders of galactose-deficient immunoglobulins

Country Status (11)

Country Link
US (1) US20240309114A1 (https=)
EP (1) EP4304579A1 (https=)
JP (1) JP2024509282A (https=)
KR (1) KR20230154900A (https=)
CN (1) CN116997337A (https=)
AU (1) AU2022232620A1 (https=)
BR (1) BR112023017702A2 (https=)
CA (1) CA3211335A1 (https=)
IL (1) IL305665A (https=)
MX (1) MX2023010424A (https=)
WO (1) WO2022192478A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013274A (es) * 2021-05-17 2023-11-30 Biohaven Therapeutics Ltd Composiciones que incluyen potenciadores de tratamientos conjugados.
EP4370157A1 (en) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
WO2024228935A1 (en) * 2023-04-29 2024-11-07 Biohaven Therapeutics Ltd. Bifunctional degraders of galactose-deficient immunoglobulins
WO2026083257A1 (en) 2024-10-14 2026-04-23 Biohaven Therapeutics Ltd. Antigen-specific degraders of immunoglobulin a and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440191B2 (en) * 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
PL2991683T3 (pl) * 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
SG11201606761RA (en) * 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
PL3145934T3 (pl) * 2014-05-19 2021-08-16 Pfizer Inc. Podstawione związki 6,8-dioksabicyklo[3.2.1]oktano-2,3-diolu jako środki kierujące do ASGPR
EP3773727A4 (en) * 2018-04-09 2022-05-04 Yale University BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS

Also Published As

Publication number Publication date
US20240309114A1 (en) 2024-09-19
MX2023010424A (es) 2023-09-18
WO2022192478A1 (en) 2022-09-15
EP4304579A1 (en) 2024-01-17
KR20230154900A (ko) 2023-11-09
CA3211335A1 (en) 2022-09-15
JP2024509282A (ja) 2024-02-29
BR112023017702A2 (pt) 2023-12-12
AU2022232620A1 (en) 2023-09-21
CN116997337A (zh) 2023-11-03

Similar Documents

Publication Publication Date Title
IL305665A (en) Bifunctional degraders of galactose-deficient immunoglobulins
JP7617974B2 (ja) シクロデキストリンタンパク質薬物コンジュゲート
KR102938500B1 (ko) 항체 약물 접합제용 친수성 링커
IL274236A (en) Proline-fastened peptides and their uses
JP7587240B2 (ja) 抗体-ペイロードコンジュゲートの調製のための化合物及びその使用
CN120665147A (zh) 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
IL274651A (en) Glucocorticoid receptor agonist and immunoconjugates thereof
CN114728073A (zh) 药物从生物活性化合物的内化缀合物的选择性释放
JP2022500413A (ja) Toll様受容体アゴニストの抗体コンジュゲート
CN120835793A (zh) 用于降解自身抗体的溶酶体靶向双功能分子
CN121038815A (zh) 半乳糖缺陷型免疫球蛋白的双功能降解剂
JP2018502045A (ja) タンパク薬物複合体で使用するためのリンカーに関連する材料および方法
AU2019350536B2 (en) Sulfomaleimide-based linkers and corresponding conjugates
IL315341A (en) METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
WO2012093733A1 (ja) 抗シグナルペプチド抗体の製造方法
Du et al. Diphtheria toxoid-derived T-helper epitope and α-galactosylceramide synergistically enhance the immunogenicity of glycopeptide antigen
KR20240012381A (ko) 세포독성제를 전달하기 위한 mate 기술을 사용한 항체 약물 접합체
US20240383961A1 (en) Conjugated antibodies for treating diseases
WO2024048490A1 (ja) 変異Fc領域を含む抗体薬物コンジュゲート
KR101536037B1 (ko) 아포리포단백질을 포함하는 항체-약물 결합체
WO2022097500A1 (ja) ペプチド架橋剤及び当該架橋剤で架橋された架橋ペプチド
EP2115001A1 (en) Coupling of antibody polypeptides at the c-terminus
HK40076663A (en) Selective drug release from internalized conjugates of biologically active compounds
WO2026026939A1 (zh) 抗cd74抗体、抗体-药物缀合物及其制备方法和用途
WO2025111600A1 (en) Compositions and methods for lipidated peptide-based modulators of hla-e